No Data
No Data
Some Investors May Be Worried About DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital
Dashenlin Pharmaceutical Group (603233.SH) has accumulated a repurchase of 0.2036% of its shares.
On July 2, Gelonhui reported that as of June 30, 2024, Dashenlin (603233.SH) had repurchased a total of 2,318,266 shares, accounting for 0.2036% of the total share capital, with a maximum purchase price of 22.81 yuan/share and a minimum purchase price of 14.70 yuan/share. The total amount paid was 41.1703 million yuan.
Investors Three-year Losses Continue as DaShenLin Pharmaceutical Group (SHSE:603233) Dips a Further 11% This Week, Earnings Continue to Decline
Dashenlin Pharmaceutical Group (603233.SH) plans to distribute a dividend of 0.31 yuan per share in 2023, with ex-rights and ex-dividend on June 21st.
Dashenlin Pharmaceutical Group (603233.SH) announced that the annual equity distribution plan for 2023 is to distribute to all shareholders...
Dashenlin Pharmaceutical Group (603233.SH): The legal representative has been changed to Ke Guoqiang.
Dashenlin Pharmaceutical Group (603233.SH) announced on June 11th that the company has recently completed the registration procedures for legal representative change, operation scope change, and charter recording, and obtained the business license issued by Guangdong Provincial Market Supervision Administration. The company's legal representative has been changed to Mr. Ke Guoqiang.
Is DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Trading At A 37% Discount?
No Data